STAT+: Pharmalittle: Moderna Covid-19 vaccine is effective in adolescents; U.S. lawmakers pitch a bill to create ‘biobonds’

Good morning, everyone, and how are you today? We are doing just fine, thank you, despite the cloudy skies looming over the Pharmalot campus, where things have settled down now that the short person is hunched over a laptop and the official mascot has assumed his formal snoozing positions. As for us, we are dutifully concocting a few needed cups of stimulation as we dig in for another busy day. No doubt, you can relate. So time to get cracking. As always, we have assembled some items of interest. So hoist your own cup to a successful day, and drop us a line when something interesting arises. …

Moderna (MRNA) reported that its Covid-19 vaccine was effective in children aged 12 to 17 in a new study, a finding that could clear the way for a second shot for use in adolescents, The Associated Press writes. The company said the vaccine induced immune responses among children that were comparable to those seen in a study of adults last year. There were no cases of symptomatic Covid-19 among vaccine recipients, suggesting 100% vaccine efficacy in adolescents, though overall very few among the 3,700 children in the study got sick.

Continue to STAT+ to read the full story…